碳离子放疗再照射治疗复发性涎腺肿瘤:CNAO二期试验结果
结论认为CIRT是再照射的良好选择且毒性可接受,需更长期随访评估疗效。
要点
- 再照射中位CIRT剂量60 Gy[RBE],分次3 Gy[RBE]。
- 1年及2年无进展生存率71.7%和52.2%。
核心结论
- CIRT是再照射不可手术复发性涎腺肿瘤的良好选择,急性和晚期毒性可接受。
- 需更长随访时间评估CIRT在涎腺肿瘤再照射中的有效性。
主要发现
- 74.5%患者为腺样囊性癌,rcT4a占51%、rcT4b占37%。
- 再照射期间G1毒性19例(37.3%)、G2 19例(37.3%)、G3 2例(3.9%)。
- 1年及2年无进展生存率分别为71.7%和52.2%,总生存率分别为90.2%和64%。
关键数值与推荐
- 既往光子放疗中位剂量60 Gy。
- CIRT中位剂量60 Gy[RBE],平均分次3 Gy[RBE]。
- 中位随访时间19个月。
临床怎么用
- 对不可手术复发性涎腺肿瘤可考虑CIRT再照射,需关注晚期G3毒性风险。
- 治疗决策时应结合既往光子放疗剂量60 Gy及再照射CIRT 60 Gy[RBE]的毒性数据。
局限性
- 中位随访仅19个月,作者指出需更长随访评估有效性。
- 原文为II期单中心报告,未报告对照数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To report oncologic and functional outcomes in terms of tumor control and toxicity of carbon ion radiotherapy (CIRT) in reirradiation setting for recurrent salivary gland tumors at CNAO. METHODS: From November 2013 to September 2016, 51 consecutive patients with inoperable recurrent salivary gland tumors were retreated with CIRT in the frame of the phase II protocol CNAO S14/2012C for recurrent head and neck tumors. RESULTS: Majority of pts (74.5%) had adenoid cystic carcinoma, mainly rcT4a (51%) and rcT4b (37%). Median dose of prior photon based radiotherapy was 60 Gy. Median dose of CIRT was 60 Gy [RBE] at a mean of 3 Gy [RBE] per fraction. During reirradiation, 19 patients (37.3%) experienced grade G1 toxicity, 19 pts (37.3%) had G2 and 2 pts (3.9%) had G3. Median follow up time was 19 months. Twenty one (41.2%) patients had stable disease and 30 (58.8%) tumor progression at the time of last follow up. Furthermore, 9 (18%) patients had G1 late toxicity, 19 (37%) had G2 and 9 (17. 5%) had G3. Using the Kaplan Meier method, progression free survival (actuarial) at one and two years were 71.7% and 52.2% respectively. Estimated overall survival (actuarial) at one and two years were 90.2% and 64%, respectively. CONCLUSIONS: CIRT is a good option for retreatment of inoperable recurrent salivary gland tumors with acceptable rates of acute and late toxicity. Longer follow up time is needed to assess the effectiveness of CIRT in reirradiation setting of salivary gland tumors.
引用
- Vischioni B, Dhanireddy B, Severo C, et al. Reirradiation of salivary gland tumors with carbon ion radiotherapy at CNAO. Radiother Oncol. 2020. PMID: 32044529. doi:10.1016/j.radonc.2020.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。